Biotech · Private company
AbelZeta Inc.
Track this companyFree. Adds AbelZeta Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials53 recruiting or active
Pipeline programs5From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline5
- C-CAR168Phase 2 · Lupus Nephritis (LN)ClinicalTrials.gov · fetched Nov 12, 2026
- C-CAR168Phase 2 · Multiple SclerosisClinicalTrials.gov · fetched Nov 12, 2026
- Prizloncabtagene AutoleucelPhase 2 · Large B Cell LymphomaClinicalTrials.gov · fetched Nov 12, 2026
- C-CAR168Phase 1 · Systemic Sclerosis (SSc)ClinicalTrials.gov · fetched Nov 12, 2026
- C-TIL051Phase 1 · Metastatic Non Small Cell Lung CancerClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials5
- Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell TherapyPHASE2 · NOT_YET_RECRUITING · started May 1, 2027ClinicalTrials.gov NCT07875413 · fetched Nov 12, 2026
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Systemic Sclerosis (SSc) Refractory to Standard TherapyPHASE1 · NOT_YET_RECRUITING · started Mar 1, 2027ClinicalTrials.gov NCT07854483 · fetched Nov 12, 2026
- C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard TherapyPHASE1_PHASE2 · NOT_YET_RECRUITING · started Feb 1, 2027ClinicalTrials.gov NCT07825389 · fetched Nov 12, 2026
- C-CAR168 CAR T Cell Therapy for Refractory Autoimmune DiseasePHASE1_PHASE2 · WITHDRAWN · started Jul 1, 2026ClinicalTrials.gov NCT06935474 · fetched Nov 12, 2026
- C-TIL051 in Non-Small Cell Lung CancerPHASE1 · TERMINATED · started Feb 29, 2024ClinicalTrials.gov NCT05676749 · fetched Nov 12, 2026